首页|Single-cell immune landscape of measurable residual disease in acute myeloid leukemia

Single-cell immune landscape of measurable residual disease in acute myeloid leukemia

扫码查看
Measurable residual disease(MRD)is a powerful prognostic factor of relapse in acute myeloid leukemia(AML).We applied the single-cell RNA sequencing to bone marrow(BM)samples from patients with(n=20)and without(n=12)MRD after allogeneic hematopoietic stem cell transplantation.A comprehensive immune landscape with 184,231 cells was created.Compared with CD8+T cells enriched in the MRD-negative group(MRD-_CD8),those enriched in the MRD-positive group(MRD+_CD8)showed lower expression levels of cytotoxicity-related genes.Three monocyte clusters(i.e.,MRD+_M)and three B-cell clusters(i.e.,MRD+_B)were enriched in the MRD-positive group.Con-version from an MRD-positive state to an MRD-negative state was accompanied by an increase in MRD-_CD8 clusters and vice versa.MRD-enriched cell clusters employed the macrophage migration inhibitory factor pathway to regulate MRD-_CD8 clusters.These findings revealed the characteristics of the immune cell landscape in MRD positivity,which will allow for a better understanding of the immune mechanisms for MRD conversion.

acute myeloid leukemiameasurable residual diseaseimmune landscapesingle-cell RNA sequencingallogeneic hematopoietic stem cell transplantation

Xiaodong Mo、Weilong Zhang、Guomei Fu、Yingjun Chang、Xiaohui Zhang、Lanping Xu、Yu Wang、Chenhua Yan、Mengzhu Shen、Qiuxia Wei、Changjian Yan、Xiaojun Huang

展开 >

Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China

Department of Hematology,Lymphoma Research Center,Peking University Third Hospital,Beijing,100191,China

Peking-Tsinghua Center for Life Sciences,Academy for Advanced Interdisciplinary Studies,Peking University,Beijing 100044,China

Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies,Chinese Academy of Medical Sciences,Beijing 100044,China

展开 >

2024

中国科学:生命科学(英文版)
中国科学院

中国科学:生命科学(英文版)

CSTPCD
影响因子:0.806
ISSN:1674-7305
年,卷(期):2024.67(11)